NSAIDs-COX-2 Inhibitors-Risks and Benefits
Journal
Pharmacovigilance
Pages
583-602
Date Issued
2007
Author(s)
Abstract
This chapter contains sections titled: Introduction Post-Marketing Cardiovascular Safety Signal Cardiovascular Safety Signal Evaluation Large Trials of COX-2 Inhibitors in Disease Prevention (Table 47.1) Meta-Analysis of COX-2 Inhibitors and Cardiovascular Outcomes Observational Studies Published After the Withdrawal of Rofecoxib Cardiovascular Safety of Other COX-2 Inhibitors Comments References
SDGs
Type
book